Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 23-26 October 2023

Chair: Sabine Straus – Vice-Chair: Martin Huber

23 October 2023, 10:30 – 19:45, via teleconference
24 October 2023, 08:30 – 19:45, via teleconference
25 October 2023, 08:30 – 19:45, via teleconference
26 October 2023, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)
09 November 2023, 09:00 – 12:00, via teleconference

Health and safety information

In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).

1 26 October 2023 - Bupivacaine, meloxicam - ZYNRELEF - PSUSA/00010880/202303 - update of action
Table of contents

1. Introduction 10
   1.1. Welcome and declarations of interest of members, alternates and experts 10
   1.2. Agenda of the meeting on 23-26 October 2023 10
   1.3. Minutes of the previous meeting on 25-28 September 2023 10

2. EU referral procedures for safety reasons: urgent EU procedures 10
   2.1. Newly triggered procedures 10
   2.2. Ongoing procedures 10
   2.3. Procedures for finalisation 10

3. EU referral procedures for safety reasons: other EU referral procedures 10
   3.1. Newly triggered procedures 10
   3.2. Ongoing procedures 11
   3.3. Procedures for finalisation 11
   3.4. Re-examination procedures 11
   3.5. Others 11

4. Signals assessment and prioritisation 11
   4.1. New signals detected from EU spontaneous reporting systems 11
      4.1.1. Elasomeran - SPIKEVAX (CAP) 11
      4.1.2. Esomeprazole - NEXIUM CONTROL (CAP); NAP 11
      4.1.3. Osimertinib – TAGRISSO (CAP) 12
      4.1.4. Tozinameran - COMIRNATY (CAP) 12
   4.2. New signals detected from other sources 12
      4.2.1. Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/SDA/006 12
      4.2.2. Dapagliflozin – EDISTRIDE (CAP) - EMEA/H/C/004161/SDA/015, FORXIGA (CAP) - EMEA/H/C/002322/SDA/028, EBYMECT (CAP) - EMEA/H/C/004162/SDA/014, XIGDUO (CAP) - EMEA/H/C/002672/SDA/017, QTERN (CAP) - EMEA/H/C/004057/SDA/009 12
   4.3. Signals follow-up and prioritisation 12
      4.3.1. Variation procedure(s) resulting from signal evaluation 13
### 5. Risk management plans (RMPs)

#### 5.1. Medicines in the pre-authorisation phase

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab</td>
<td>EMEA/H/C/005723</td>
</tr>
<tr>
<td>Catumaxomab</td>
<td>EMEA/H/C/005697</td>
</tr>
<tr>
<td>Cefepime, enmetazobactam</td>
<td>EMEA/H/C/005431</td>
</tr>
<tr>
<td>Danicopan</td>
<td>EMEA/H/C/005517, PRIME, Orphan</td>
</tr>
<tr>
<td>Influenza vaccine (H5N1)</td>
<td>EMEA/H/C/006052</td>
</tr>
<tr>
<td>Lecanemab</td>
<td>EMEA/H/C/005966</td>
</tr>
<tr>
<td>Paliperidone</td>
<td>EMEA/H/C/006185</td>
</tr>
<tr>
<td>Polihexanide</td>
<td>EMEA/H/C/005858, Orphan</td>
</tr>
<tr>
<td>Pomalidomide</td>
<td>EMEA/H/C/006195</td>
</tr>
</tbody>
</table>

#### 5.2. Medicines in the post-authorisation phase – PRAC-led procedures

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone - OZURDEX (CAP)</td>
<td>EMEA/H/C/001140/II/0044</td>
</tr>
<tr>
<td>Emtricitabine, tenofovir disoproxil - EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP)</td>
<td>EMEA/H/C/005243/WS2515/0018; VIMPAT (CAP) - EMEA/H/C/000863/WS2515/0100</td>
</tr>
<tr>
<td>Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005208/II/0023, Orphan</td>
<td></td>
</tr>
<tr>
<td>Lenvatinib - LENVIMA (CAP)</td>
<td>EMEA/H/C/003727/II/0053</td>
</tr>
<tr>
<td>Tixagevimab, cilgavimab - EVUSHELD (CAP)</td>
<td>EMEA/H/C/005788/II/0013</td>
</tr>
<tr>
<td>Tofacitinib - XELJANZ (CAP)</td>
<td>EMEA/H/C/004214/II/0054</td>
</tr>
</tbody>
</table>

#### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMA Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alglucosidase alfa - MYOZYME (CAP)</td>
<td>EMEA/H/C/000636/II/0095</td>
</tr>
<tr>
<td>Aripiprazole - ABILIFY MAINTENA (CAP)</td>
<td>EMEA/H/C/002755/X/0045</td>
</tr>
<tr>
<td>Avapritinib - AYVAKYT (CAP)</td>
<td>EMEA/H/C/005208/II/0023, Orphan</td>
</tr>
<tr>
<td>Azacitidine - AZACITIDINE ACCORD (CAP)</td>
<td>EMEA/H/C/005147/X/0013</td>
</tr>
<tr>
<td>Bempedoic acid - NILEMDO (CAP)</td>
<td>EMEA/H/C/004958/II/0031</td>
</tr>
<tr>
<td>Budesonide, formoterol fumarate dihydrate - BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. (CAP)</td>
<td>EMEA/H/C/004837/II/0012/G</td>
</tr>
<tr>
<td>Cariprazine - REAGILA (CAP)</td>
<td>EMEA/H/C/002770/II/0034</td>
</tr>
<tr>
<td>Cariprazine - REAGILA (CAP)</td>
<td>EMEA/H/C/002770/X/0033</td>
</tr>
<tr>
<td>Concentrate of proteolytic enzymes enriched in bromelain - NEXOBRID (CAP)</td>
<td>EMEA/H/C/0002246/II/0058</td>
</tr>
<tr>
<td>Dabigatran etexilate - PRADAXA (CAP)</td>
<td>EMEA/H/C/000829/II/0017/G</td>
</tr>
<tr>
<td>Denosumab - PROLIA (CAP)</td>
<td>EMEA/H/C/001120/II/0099</td>
</tr>
<tr>
<td>Faricimab - VABYSMO (CAP)</td>
<td>EMEA/H/C/005642/II/0005</td>
</tr>
<tr>
<td>Hydroxycarbamide - XROMI (CAP)</td>
<td>EMEA/H/C/004837/II/0019</td>
</tr>
<tr>
<td>Idecabtagene vicleucel - ABECMA (CAP)</td>
<td>EMEA/H/C/004662/II/0031, Orphan</td>
</tr>
<tr>
<td>Infliximab - REMSIMA (CAP)</td>
<td>EMEA/H/C/002576/II/0133/G</td>
</tr>
<tr>
<td>5.3.17.</td>
<td>Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - EMEA/H/C/004993/II/0043</td>
</tr>
<tr>
<td>5.3.18.</td>
<td>Mecasermin - INCRELEX (CAP) - EMEA/H/C/000704/II/0080</td>
</tr>
<tr>
<td>5.3.19.</td>
<td>Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0039</td>
</tr>
<tr>
<td>5.3.20.</td>
<td>Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0136</td>
</tr>
<tr>
<td>5.3.21.</td>
<td>Opicapone - ONGENTYS (CAP) - EMEA/H/C/002790/WS2552/0060; ONTILYV (CAP) - EMEA/H/C/005782/WS2552/0015</td>
</tr>
<tr>
<td>5.3.22.</td>
<td>Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/X/0031/G</td>
</tr>
<tr>
<td>5.3.23.</td>
<td>Pregabalin - LYRICA (CAP) - EMEA/H/C/005553/II/0011, Orphan</td>
</tr>
<tr>
<td>5.3.24.</td>
<td>Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0138</td>
</tr>
<tr>
<td>5.3.25.</td>
<td>Pralsetinib - GAVRETO (CAP) - EMEA/H/C/005413/II/0012</td>
</tr>
<tr>
<td>5.3.26.</td>
<td>Saxagliptin - ONGLYZA (CAP) - EMEA/H/C/001039/II/0057</td>
</tr>
<tr>
<td>5.3.27.</td>
<td>Selexipag - UPTRAVI (CAP) - EMEA/H/C/003774/X/0038</td>
</tr>
<tr>
<td>5.3.28.</td>
<td>Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0021</td>
</tr>
<tr>
<td>5.3.29.</td>
<td>Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0022</td>
</tr>
<tr>
<td>5.3.30.</td>
<td>Sotorasib - LUMYKRAS (CAP) - EMEA/H/C/005522/II/0007</td>
</tr>
<tr>
<td>5.3.31.</td>
<td>Spesolimab - SPEVIGO (CAP) - EMEA/H/C/005874/X/0006/G</td>
</tr>
<tr>
<td>5.3.32.</td>
<td>Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/003774/X/0038</td>
</tr>
<tr>
<td>5.3.33.</td>
<td>Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0188/G</td>
</tr>
</tbody>
</table>

### 6. Periodic safety update reports (PSURs) 27

| 6.1.1. | PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only | 27 |
| 6.1.1. | Avacopan - TAVNEOS (CAP) - PSUSA/00010967/202303 | 27 |
| 6.1.2. | Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202303 | 27 |
| 6.1.3. | Betaine anhydrous - CYSTADANE (CAP) - PSUSA/00000390/202302 | 27 |
| 6.1.4. | Bupivacaine, meloxicam - ZYNRELEF - PSUSA/00010880/202303 | 27 |
| 6.1.5. | Cabotegravir - VOCABRIA (CAP) - PSUSA/00010900/202303 | 28 |
| 6.1.6. | Cenobamate - ONTOZRY (CAP) - PSUSA/00010921/202303 | 28 |
| 6.1.7. | Certolizumab - CIMZIA (CAP) - PSUSA/00000624/202303 | 28 |
| 6.1.8. | Ciclosporin - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202303 | 28 |
| 6.1.9. | Dabigatran - PRADAXA (CAP) - PSUSA/0000009/202303 | 28 |
| 6.1.10. | Dimethyl fumarate - SKILARENCE (CAP) - PSUSA/00010647/202303 | 28 |
| 6.1.11. | Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202303 | 29 |
| 6.1.12. | Duvelisib - COPIKTRA (CAP) - PSUSA/00010939/202303 | 29 |
| 6.1.13. | Eftrenonacog alfa - ALPROLIX (CAP) - PSUSA/00010499/202303 | 29 |
| 6.1.15. | Fingolimod - GILENYA (CAP) - PSUSA/00010362/202303 | 29 |
| 6.1.16. | Gozetotide - LOCAMETZ (CAP) - PSUSA/00010362/202303 | 29 |
| 6.1.17. | Ibritumomab tiuxetan - ZEVALIN (CAP) - PSUSA/00010170/202302 | 30 |
6.1.18. Idecabtagene vicleucel - ABECMA (CAP) - PSUSA/00010954/202303 .......................................................... 30
6.1.19. Lasmiditan - RAYVOW (CAP) - PSUSA/00011011/202304 .......................................................... 30
6.1.20. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202303 .......................................................... 31
6.1.21. Lutetium (177LU) vipivotide tetraxetan - PLUVICTO (CAP) - PSUSA/00011031/202303 .......... 31
6.1.22. Maralixibat - LIVMARLI (CAP) - PSUSA/00011032/202303 .......................................................... 31
6.1.23. Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202303 .......................................................... 31
6.1.24. Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202303 ................................................. 31
6.1.25. Niraparib - ZEJULA (CAP) - PSUSA/00010655/202303 .......................................................... 31
6.1.27. Ofatumumab - KESIMPTA (CAP) - PSUSA/00010927/202303 .......................................................... 32
6.1.28. Olipudase alfa - XENPOZYME (CAP) - PSUSA/00011031/202303 ................................................. 32
6.1.29. Oritavancin - TENKASI (CAP) - PSUSA/00010368/202303 .......................................................... 32
6.1.30. Ponesimod - PONVORY (CAP) - PSUSA/00010940/202303 .......................................................... 32
6.1.31. Rilpivirine - REKAMBYS (CAP) - PSUSA/00010901/202303 .......................................................... 32
6.1.32. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202303 .......................................................... 33
6.1.33. Selinexor - NEXPOVIO (CAP) - PSUSA/00010926/202303 .......................................................... 33
6.1.34. Selumetinib - KOSELUDO (CAP) - PSUSA/00010936/202304 .......................................................... 33
6.1.35. Siponimod - MAYZENT (CAP) - PSUSA/00010818/202303 .......................................................... 33
6.1.36. Soliramfetol - SUNOSI (CAP) - PSUSA/00010831/202303 .......................................................... 33
6.1.37. Tebentafusp - KIMMTRAK (CAP) - PSUSA/00010991/202303 .......................................................... 34
6.1.38. Tepotinib - TEPMETKO (CAP) - PSUSA/00010979/202303 .......................................................... 34
6.1.39. Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202303 .......................................................... 34
6.1.40. Trifluridine, tipiracil - LONSURF (CAP) - PSUSA/00010517/202303 ................................................. 34
6.1.41. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202303 .......................................................... 34
6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) .......................................................... 35
6.2.1. Pramipexole - MIRAPEXIN (CAP); SIFROL (CAP); NAP - PSUSA/00002491/202304 .......... 35
6.2.2. Timolol, travoprost - DUOTRAV (CAP); NAP - PSUSA/00002962/202302 ................................................. 35
6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only .......................................................... 35
6.3.1. BCG (bacillus calmette-guérin) for Immunotherapy (NAP) - PSUSA/0000303/202303 .......... 35
6.3.2. BCG vaccine (freeze-dried) (NAP) - PSUSA/0000304/202303 .......................................................... 35
6.3.3. Bicalutamide (NAP) - PSUSA/0000407/202302 .......................................................... 35
6.3.4. Dienogest, ethinylestradiol (NAP) - PSUSA/00001057/202303 .......................................................... 36
6.3.5. Ethosuximide (NAP) - PSUSA/00001316/202303 .......................................................... 36
6.3.6. Fluconazole (NAP) - PSUSA/00001404/202303 .......................................................... 36
6.3.7. Furosemide, spironolactone (NAP) - PSUSA/00001493/202303 .......................................................... 36
6.3.8. Human plasma (NAP) - PSUSA/00001635/202302 .......................................................... 36
6.3.9. Oxycodone (NAP) - PSUSA/00002254/202304 .......................................................... 36
6.4. Follow-up to PSUR/PSUSA procedures ................................................................. 37
6.4.1. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/LEG 017.2 ......................... 37

6.5. Variation procedure(s) resulting from PSUSA evaluation ...................................... 37
6.5.1. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0243................................. 37
6.5.2. Laronidase - ALDURAZYME (CAP) - EMEA/H/C/000477/II/0085 ......................... 37

6.6. Expedited summary safety reviews ...................................................................... 38

7. Post-authorisation safety studies (PASS) ................................................................. 38

7.1. Protocols of PASS imposed in the marketing authorisation(s) .............................. 38
7.1.1. Alemtuzumab - Lemtrada (CAP) - EMEA/H/C/PSA/S/0107 ................................. 38
7.1.2. Valproate (NAP) - EMEA/H/N/PSP/J/0075.13 ......................................................... 38

7.2. Protocols of PASS non-imposed in the marketing authorisation(s) ...................... 38
7.2.1. Avatrombopag - DOPTELET (CAP) - EMEA/H/C/004722/MEA 003.4 .................. 38
7.2.2. Cannabidiol - EPIDYOLEX (CAP) - EMEA/H/C/004675/MEA 007.3 ..................... 39
7.2.3. Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - EMEA/H/C/006058/MEA 008 ....................... 39
7.2.4. Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - EMEA/H/C/006058/MEA 009 ....................... 39
7.2.5. Ivosidenib - TIBSOVO (CAP) - EMEA/H/C/005936/MEA 003 ................................. 39
7.2.6. Linaclotide - CONSTELLA (CAP) - EMEA/H/C/002490/MEA 009.7 ................. 40
7.2.7. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 001 ...................... 40
7.2.8. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 002 ...................... 40
7.2.9. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.7 .................. 41
7.2.10. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.7 .................. 41
7.2.11. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.5 .................. 41
7.2.12. Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 002.1 ................. 41
7.2.13. Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 005.1 .................... 42
7.2.14. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 037.5 ............... 42
7.2.15. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 017.1 ...................... 42
7.2.16. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 044.17 ................. 42
7.2.17. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - EMEA/H/C/005830/MEA 005.1 ........................................ 43
7.2.18. Voclosporin - LUPKYNIS (CAP) - EMEA/H/C/005256/MEA 002.1 .................... 43

7.3. Results of PASS imposed in the marketing authorisation(s) ............................. 43
7.3.1. Valproate (NAP) - EMEA/H/N/PSR/J/0043 ......................................................... 43
7.3.2. Valproate (NAP) - EMEA/H/N/PSR/J/0045 ......................................................... 43

7.4. Results of PASS non-imposed in the marketing authorisation(s) ...................... 44
7.4.1. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0093 .................... 44
7.4.2. Belimumab - BENLYSTA (CAP) - EMEA/H/C/002015/II/0116 ......................... 44
7.4.3. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0082 ............... 44
7.4.4. Elasomber - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0110 ......................... 45
7.4.5. Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/WS2519/0071/G; MODIGRAF (CAP) - EMEA/H/C/000954/WS2519/0046/G ................................................................. 45

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation ................................................................. 45
7.5.1. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/SOB 009.1 ............................................ 45
7.5.2. Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/004480/ANX 002.6 ...................... 46
7.5.3. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 005 ........................................ 46
7.5.4. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.9 ................................................................. 46
7.5.5. Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 002 ........................................ 46
7.5.6. Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 003 ........................................ 46
7.5.7. Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 004 ........................................ 47
7.5.8. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/MEA 006.6 ........................................ 47
7.5.9. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/MEA 003.15 ................................................................. 47

7.6. Others .................................................................................................................. 47

7.7. New Scientific Advice ........................................................................................... 47

7.8. Ongoing Scientific Advice ..................................................................................... 48

7.9. Final Scientific Advice (Reports and Scientific Advice letters) .............................. 48

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 48
8.1. Annual reassessments of the marketing authorisation ........................................ 48
8.1.1. Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0062 (without RMP) ................. 48
8.1.2. Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0036 (without RMP) ........... 48
8.2. Conditional renewals of the marketing authorisation ........................................ 48
8.3. Renewals of the marketing authorisation ............................................................ 48
8.3.1. Lusutrombopag - MULPLEO (CAP) - EMEA/H/C/004720/R/0018 (without RMP) ............. 48
8.3.2. Paclitaxel - PAZENIR (CAP) - EMEA/H/C/004441/R/0015 (with RMP) ............................. 49
8.3.3. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/R/0038 (without RMP) .................... 49
8.3.4. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/R/0039 (without RMP) .................. 49
8.3.5. Treosulfan - TRECONDI (CAP) - EMEA/H/C/004751/R/0019 (without RMP) .................. 49
8.3.6. Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/R/0017 (without RMP) .................... 49

9. Product related pharmacovigilance inspections 49
9.1. List of planned pharmacovigilance inspections .................................................. 49
9.2. Ongoing or concluded pharmacovigilance inspections ....................................... 50
9.3. Others .................................................................................................................. 50

10. Other safety issues for discussion requested by the CHMP or the EMA 50
10.1. Safety related variations of the marketing authorisation .................................... 50
10.2. Timing and message content in relation to Member States’ safety announcements

10.3. Other requests

10.4. Scientific Advice

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. Hydroxyethyl starch (NAP) - DE/H/xxxx/WS/1360, DE/H/xxxx/WS/1452

11.2. Other requests

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

12.1.2. Vote by proxy

12.2. Coordination with EMA Scientific Committees or CMDh-v

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

12.4. Cooperation within the EU regulatory network

12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update

12.4.2. PRAC strategic review and learning meeting (SRLM) under the Spanish presidency of the European Union (EU) Council – Madrid, Spain, 14 - 15 November 2023 - agenda

12.5. Cooperation with International Regulators

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

12.7. PRAC work plan

12.8. Planning and reporting

12.8.1. EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q3 2023 and predictions

12.8.2. PRAC workload statistics – Q3 2023

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

12.9.2. Pharmacovigilance inspections

12.9.3. Pharmacovigilance audits

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

12.10.3. PSURs repository

12.10.4. Union reference date list – consultation on the draft list

12.10.5. Periodic safety update reports single assessment (PSUSA) – review of ‘other considerations’ section in the assessment report – update and proposed way forward

12.11. Signal management

12.12. **Adverse drug reactions reporting and additional reporting** ................................. 53
  12.12.1. Management and reporting of adverse reactions to medicinal products ............. 53
  12.12.2. Additional monitoring ....................................................................................... 53
  12.12.3. List of products under additional monitoring – consultation on the draft list .......... 53
12.13. **EudraVigilance database** .................................................................................. 54
  12.13.1. Activities related to the confirmation of full functionality .................................... 54
12.14. **Risk management plans and effectiveness of risk minimisations** ......................... 54
  12.14.1. Risk management systems ................................................................................ 54
  12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations .... 54
12.15. **Post-authorisation safety studies (PASS)** .......................................................... 54
  12.15.1. Post-authorisation Safety Studies – imposed PASS .............................................. 54
  12.15.2. Post-authorisation Safety Studies – non-imposed PASS ....................................... 54
12.16. **Community procedures** .................................................................................... 54
  12.16.1. Referral procedures for safety reasons ............................................................... 54
12.17. **Renewals, conditional renewals, annual reassessments** ........................................ 54
12.18. **Risk communication and transparency** ................................................................. 54
  12.18.1. Public participation in pharmacovigilance .......................................................... 54
  12.18.2. Safety communication ....................................................................................... 55
12.19. **Continuous pharmacovigilance** .......................................................................... 55
  12.19.1. Incident management ....................................................................................... 55
12.20. **Impact of pharmacovigilance activities** ................................................................. 55
12.21. **Others** ............................................................................................................... 55
  12.21.1. Good Pharmacovigilance Practice (GVP) – end-of-year update for 2023 and planning for 2024 .................................................................................................................................................. 55
  12.21.2. Presentation of draft reflection paper on ‘Use of real-world data to generate real-world evidence in non-interventional studies’ ........................................................................................................ 55

13. **Any other business** ................................................................................................. 55
14. **Explanatory notes** .................................................................................................. 56
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 23-26 October 2023. See November 2023 PRAC minutes (to be published post December 2023 PRAC meeting).

1.2. **Agenda of the meeting on 23-26 October 2023**

*Action:* For adoption

1.3. **Minutes of the previous meeting on 25-28 September 2023**

*Action:* For adoption

2. **EU referral procedures for safety reasons: urgent EU procedures**

2.1. **Newly triggered procedures**

None

2.2. **Ongoing procedures**

None

2.3. **Procedures for finalisation**

None

3. **EU referral procedures for safety reasons: other EU referral procedures**

3.1. **Newly triggered procedures**

None
3.2. **Ongoing procedures**
None

3.3. **Procedures for finalisation**
None

3.4. **Re-examination procedures**
None

3.5. **Others**
None

### 4. Signals assessment and prioritisation

4.1. **New signals detected from EU spontaneous reporting systems**

4.1.1. **Elasomeran - SPIKEVAX (CAP)**

Applicant: Moderna Biotech Spain, S.L.
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Signal of postmenopausal haemorrhage
**Action:** For adoption of PRAC recommendation
EPITT 20015 – New signal
Lead Member State(s): DK

4.1.2. **Esomeprazole - NEXIUM CONTROL (CAP); NAP**

Applicant: GlaxoSmithKline Dungarvan Ltd (Nexium Control), various
PRAC Rapporteur: Rugile Pilviniene
Scope: Signal of Erectile dysfunction
**Action:** For adoption of PRAC recommendation
EPITT 19976 – New signal
Lead Member State(s): LT

---

2 Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
3 Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required
4.1.3. Osimertinib – TAGRISSO (CAP)

Applicant: AstraZeneca AB
PRAC Rapporteur: Menno van der Elst
Scope: Signal of progressive multifocal leukoencephalopathy

**Action:** For adoption of PRAC recommendation

EPITT 19984 – New signal
Lead Member State(s): NL

4.1.4. Tozinameran - COMIRNATY (CAP)

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Signal of postmenopausal haemorrhage

**Action:** For adoption of PRAC recommendation

EPITT 19989 – New signal
Lead Member State(s): NL

4.2. New signals detected from other sources

None

4.3. Signals follow-up and prioritisation

4.3.1. Amivantamab – RYBREVANT (CAP) - EMEA/H/C/005454/SDA/006

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Gabriele Maurer
Scope: Signal of anaphylactic reaction

**Action:** For adoption of PRAC recommendation

EPITT 19928 – Follow up to June 2023

4.3.2. Dapagliflozin – EDISTRIDE (CAP) - EMEA/H/C/004161/SDA/015, FORXIGA (CAP) - EMEA/H/C/002322/SDA/028, EBYMECT (CAP) - EMEA/H/C/004162/SDA/014, XIGDUO (CAP) - EMEA/H/C/002672/SDA/017, QTERN (CAP) - EMEA/H/C/004057/SDA/009

Applicant: AstraZeneca AB
PRAC Rapporteur: Mari Thorn
Scope: Signal of acquired phimosis and phimosis with dapagliflozin

**Action:** For adoption of PRAC recommendation
4.3.3. **Glucagon-like peptide-1 (GLP-1) receptor agonists:**
- dulaglutide – TRULICITY (CAP) - EMEA/H/C/002825/SDA/014
- exenatide – BYDUREON (CAP) - EMEA/H/C/002020/SDA/029, BYETTA (CAP) - EMEA/H/C/000698/SDA/049

Applicant: AstraZeneca AB (Bydureon, Byetta), Eli Lilly Nederland B.V. (Trulicity), Novo Nordisk A/S (Ozempic, Rybelsus, Saxenda, Victoza, Wegovy, Xultophy), Sanofi Winthrop Industrie (Lyxumia, Suliqua)

PRAC Rapporteur: Mari Thorn

Scope: Signal of thyroid cancer

**Action:** For adoption of PRAC recommendation

---

4.4. **Variation procedure(s) resulting from signal evaluation**

None

---

5. **Risk management plans (RMPs)**

5.1. **Medicines in the pre-authorisation phase**

5.1.1. **Bevacizumab - EMEA/H/C/005723**

Scope: Treatment of neovascular (wet) age-related macular degeneration (nAMD)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. **Catumaxomab - EMEA/H/C/005697**

Scope: Treatment of malignant ascites

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. **Cefepime, enmetazobactam - EMEA/H/C/005431**

Scope: Treatment of: 1) complicated urinary tract infections (including pyelonephritis); 2) hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP); 3) patients with bacteraemia that occurs in association with, or is suspected to be associated
with, any of the infections listed above and 4) infections due to aerobic Gram-negative organisms in adults with limited treatment options

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.4. Danicopan - EMEA/H/C/005517, PRIME, Orphan

**Applicant:** Alexion Europe

**Scope:** Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.5. Influenza vaccine (H5N1)\(^4\) - EMEA/H/C/006052

**Scope:** Active immunisation for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.6. Influenza vaccine (H5N1)\(^5\) - EMEA/H/C/006051

**Scope:** Prophylaxis of influenza

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.7. Lecanemab - EMEA/H/C/005966

**Scope:** Disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer’s disease and Mild Alzheimer’s disease (Early Alzheimer’s disease)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.8. Paliperidone - EMEA/H/C/006185

**Scope:** Treatment of schizophrenia

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.1.9. Polihexanide - EMEA/H/C/005858, Orphan

**Applicant:** SIFI SPA

**Scope:** Treatment of acanthamoeba keratitis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

\(^4\) Virus A/turkey/Turkey/1/2005 (H5N1) NIBERG-23 strain, HA surface antigen

\(^5\) Virus A/turkey/Turkey/1/2005 (H5N1) NIBERG-23 strain, HA surface antigen
5.1.10. Pomalidomide - EMEA/H/C/006195

Scope: Treatment of adult patients with relapsed and refractory multiple myeloma (MM) in combination with dexamethasone

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Dexamethasone - OZURDEX (CAP) - EMEA/H/C/001140/II/0044

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Submission of an updated Annex II and RMP version 11 in order to remove additional risk minimisation measure: Patient guide, audio CD (where required)

**Action:** For adoption of PRAC Assessment Report

5.2.2. Emtricitabine, tenofovir disoproxil - EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004137/WS2486/0025

Applicant: Zentiva k.s.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Submission of an updated RMP version 5.1 for Emtricitabine/Tenofovir disoproxil in line with the reference medicinal product Truvada (EMEA/H/C/WS2320)

**Action:** For adoption of PRAC Assessment Report

5.2.3. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/WS2515/0018; VIMPAT (CAP) - EMEA/H/C/000863/WS2515/0100

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP version 17.0 in order to introduce new updates including the removal of category 3 study EP0158 due to study closure by lack of enrolment, and the removal of category 3 studies (SP848 and EP0034)

**Action:** For adoption of PRAC Assessment Report

5.2.4. Lenvatinib - LENVIMA (CAP) - EMEA/H/C/003727/II/0053

Applicant: Eisai GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of section 5.1 of the SmPC in order to update safety and efficacy information for the hepatocellular carcinoma (HCC) indication, based on interim results from study E7080-M000-508 (STELLAR), listed as a category 3 PASS in the RMP. This is a non-interventional multicentre, observational, phase 4 study to evaluate the safety and
tolerability of lenvatinib in patients with advanced or unresectable HCC. RMP version 15.2 has also been submitted.

**Action:** For adoption of PRAC Assessment Report

### 5.2.5. Tixagevimab, cilgavimab - EVUSHELD (CAP) - EMEA/H/C/005788/II/0013

**Applicant:** AstraZeneca AB  
**PRAC Rapporteur:** Kimmo Jaakkola  
**Scope:** Submission of an updated RMP version 5 succession 1 to remove the commitment to conduct the PASS D8850R00006: a post-authorisation observational study of women exposed to EVUSHELD during pregnancy (O-STEREO)  

**Action:** For adoption of PRAC Assessment Report

### 5.2.6. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/II/0054

**Applicant:** Pfizer Europe MA EEIG  
**PRAC Rapporteur:** Liana Gross-Martirosyan  
**Scope:** Submission of an updated RMP version 31.1 in order to modify study A3921427 from an interventional to a non-interventional study. In addition, the MAH has taken the opportunity to update other sections of the RMP  

**Action:** For adoption of PRAC Assessment Report

### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

#### 5.3.1. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0095

**Applicant:** Sanofi B.V.  
**PRAC Rapporteur:** Nathalie Gault  
**Scope:** Update of sections 4.4 and 5.2 of the SmPC in order to update warning on immunogenicity. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information  

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.2. Aripiprazole - ABILIFY MAINTENA (CAP) - EMEA/H/C/002755/X/0045

**Applicant:** Otsuka Pharmaceutical Netherlands B.V.  
**PRAC Rapporteur:** Ulla Wändel Liminga  
**Scope:** Extension application to introduce a new pharmaceutical form associated with two new strengths (720 and 960 mg Prolonged-release suspension for injection). The RMP (version 12.1) is updated in accordance  

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.3. **Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/II/0023, Orphan**

Applicant: Blueprint Medicines (Netherlands) B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) for avapritinib based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomised, double-blind, placebo-controlled, phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. **Azacitidine - AZACITIDINE ACCORD (CAP) - EMEA/H/C/005147/X/0013**

Applicant: Accord Healthcare S.L.U.

PRAC Rapporteur: Menno van der Elst

Scope: Extension application to introduce a new pharmaceutical form associated with a new strength (10 mg/ml powder for solution for infusion) and a new route of administration (intravenous use). The RMP version 2 is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. **Bempedoic acid - NILEMDO (CAP) - EMEA/H/C/004958/II/0031**

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk, based on results from study 1002-043 (CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen]). CLEAR outcomes study is a phase 3 multi-centre randomised, double-blind, placebo-controlled study to evaluate whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly. Version 4.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor formatting changes to the product information. As part of the application, the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. **Bempedoic acid, ezetimibe - NUSTENDI (CAP) - EMEA/H/C/004959/II/0035**

Applicant: Daiichi Sankyo Europe GmbH
PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk for NUSTENDI, based on results from Study 1002-043, known as the CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen] outcomes trial, a phase 3, randomised, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7.

**Budesonide, formoterol fumarate dihydrate - BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. (CAP) - EMEA/H/C/004882/II/0012/G**

Applicant: Teva Pharma B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Grouped variations consisting of: 1) To replace the multidose dry powder inhaler to be used for the delivery of a combination of Budesonide/Formoterol fumarate dihydrate inhalation powder, as well as detect, record, store and transfer inhaler usage information to a mobile application (App); the inhaler is an integrated part of the primary packaging of the medicinal product; 2) To change the name of the medicinal product 3) To update sections 4.2 and 4.4 of the SmPC to reorganise the flow of information within these sections (as approved for DuoResp Spiromax EMEA/H/C/002348), following assessment of the same change for the reference product Symbicort Turbohaler; 4) other quality variations

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.8.

**Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/II/0034**

Applicant: Gedeon Richter Plc.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Update of sections 4.3 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The package leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.9.

**Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/X/0033**

Applicant: Gedeon Richter Plc.
PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Extension application to introduce a new pharmaceutical form (orodispersible tablets). The RMP (version 3.0) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

5.3.10. **Concentrate of proteolytic enzymes enriched in bromelain - NEXOBRID (CAP) - EMEA/H/C/002246/II/0058**

Applicant: MediWound Germany GmbH

PRAC Rapporteur: Martin Huber

Scope: Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as Study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, open label, 2-arm study aiming to demonstrate the superiority of NexoBrid treatment over standard of care (SOC) treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated accordingly. Version 9 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

5.3.11. **Dabigatran etexilate - PRADAXA (CAP) - EMEA/H/C/000829/II/0147/G**

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: A grouped application consisting of:

C.I.7.a (type IB): 1) to delete the pharmaceutical form "powder and solvent for oral solution, 6.25 mg/ml", as agreed in procedure EMEA/H/C/000829/II/0144.

C.I.4 (type II): 2) Update of section 4.1 of the SmPC in order to modify the indication following the deletion of the powder and solvent for oral solution; the package leaflet is updated accordingly. The RMP version 41.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

5.3.12. **Denosumab - PROLIA (CAP) - EMEA/H/C/001120/II/0099**

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to update a warning regarding hypocalcaemia and to include reports of life-threatening events and fatal cases occurred in the post marketing setting, particularly in patients with severe renal impairment, receiving dialysis or treatment with other calcium lowering drugs based on the cumulative review of
5.3.13. Faricimab - VABYSMO (CAP) - EMEA/H/C/005642/II/0005

Applicant: Roche Registration GmbH
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Extension of indication to include treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) for Vabysmo, based on results from the two phase 3 studies: GR41984 (BALATON) in patients with branch retinal vein occlusion (BRVO) and GR41986 (COMINO) in patients with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO). These are global, multicentre, randomised, double-masked, active comparator-controlled, parallel-group, 2-part studies evaluating the efficacy, safety, and PK of faricimab. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The package leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Hydroxycarbamide - XROMI (CAP) - EMEA/H/C/004837/II/0019

Applicant: Nova Laboratories Ireland Limited
PRAC Rapporteur: Jo Robays
Scope: Extension of indication to include the prevention of vaso-occlusive complications of sickle cell disease in children from 6 months to 2 years of age for Xromi, based on final results from the paediatric study INV543, listed as a category 3 study in the RMP; this is a single-arm, open-label, multi-centre study in children with sickle cell anaemia over 6 months of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Idecabtagene vicleucel - ABECMA (CAP) - EMEA/H/C/004662/II/0031, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP®
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel with daratumumab, pomalidomide and dexamethasone

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the product information is brought in line with the Guideline on core SmPC, labelling and package leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.16. Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - EMEA/H/C/002576/II/0133/G

Applicant: Celltrion Healthcare Hungary Kft.
PRAC Rapporteur: Kimmo Jaakkola
Scope: Grouped application comprising three type II variations (C.I.4) as follows:
1) Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (Crohn’s disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a randomised, placebo controlled, double-blind, phase 3 study to evaluate the efficacy and safety of the subcutaneous injection of CT-P13 (CT-P13 SC) as maintenance therapy in patients with moderately to severely active ulcerative colitis and study CT-P13 3.8 is a randomised, placebo-controlled, double-blind, phase 3 study to evaluate the efficacy and safety of the subcutaneous injection of CT-P13 (CT-P13 SC) as maintenance therapy in patients with moderately to severely active Crohn’s disease.
2) Update of section 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
3) Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (> 5 mg/kg) to subcutaneous maintenance dose of 120 mg every two weeks based on data from REMSWITCH study (Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH Study).
The RMP version 16.1 has also been submitted. The package leaflet and labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the product information.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - EMEA/H/C/004993/II/0043

Applicant: Seqirus Netherlands B.V.
PRAC Rapporteur: Jean-Michel Dogné
Scope: Extension of indication to include adults 50 years of age and older for Fluad Tetra, based on final results from study V118_23; this is a phase 3, randomised, observer-blind, controlled, multicentre, clinical study to evaluate immunogenicity and safety of an MF59-adjuvanted quadrivalent subunit inactivated influenza vaccine in comparison with a licensed quadrivalent influenza vaccine, in adults 50 to 64 years of age. As a consequence, sections
4.1, 4.8 and 5.1 of the SmPC are updated. The labelling and package leaflet are updated in accordance. Version 2.9 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.18. Mecasermin - INCRELEX (CAP) - EMEA/H/C/000704/II/0080

**Applicant:** Ipsen Pharma

**PRAC Rapporteur:** Kirsti Villikka

**Scope:** Update of sections 4.2, 4.6, and 4.8 of the SmPC in order to modify administration instructions recommendation regarding the monitoring of pre-prandial blood glucose in preprandial condition and in case of symptoms and to prevent the risk of lipohypertrophy, delete wording in the pregnancy section and update on number of patients with severe primary IGDF deficiency (IGFD) based on the cumulative review of safety database, scientific literature and clinical trials data. The package leaflet is updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.19. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0039

**Applicant:** Kyowa Kirin Holdings B.V.

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** Update of sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC in order to update information regarding the use of naloxegol in opioid-induced constipation (OIC) patients with cancer-related pain based on real-world data from non-interventional studies (NACASY, KYONAL, and MOVE studies), post-marketing data, and literature. The package leaflet is updated accordingly. The RMP version 8 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.20. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0136

**Applicant:** Biogen Netherlands B.V.

**PRAC Rapporteur:** Gabriele Maurer

**Scope:** Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post marketing and clinical study data. The package leaflet and Annex IID are updated accordingly. The RMP version 29.1 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.21. **Opicapone - ONGENTYS (CAP) - EMEA/H/C/002790/WS2552/0060; ONTILYV (CAP) - EMEA/H/C/005782/WS2552/0015**

Applicant: Bial Portela & Companhia S.A.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Extension of indication to include treatment of signs and symptoms of Parkinson’s Disease for Ongentys/Ontilyv, based on final results from study BIA-91067-303; this is a pivotal Phase III, multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of opicapone in patients with early idiopathic Parkinson’s Disease receiving treatment with L-DOPA plus a DDCI, and who are without signs of any motor complication. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted (only applicable to Ongentys) to reflect the changes made upon approval of the informed consent application, to keep consistency between the eCTD lifecycles of the two marketing authorisations (Ongentys and Ontilyv). Furthermore, the product information is brought in line with the latest QRD template version 10.3. In addition, as part of the application the MAH is requesting a 1-year extension of the market protection.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

5.3.22. **Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/X/0031/G**

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Kirsti Villikka

Scope: Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 6 to 18 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer for oral suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.8, 4.9, 5.1 and 6.5 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

5.3.23. **Pegcetacoplan - ASPAVELI (CAP) - EMEA/H/C/005553/II/0011, Orphan**

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) not previously treated with a complement inhibitor for ASPAVELI, based on final results from study APL2-308. This is a phase III, randomised, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.
5.3.24. Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0138

Applicant: Merck Sharp & Dohme B.V.
PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include Keytruda in combination with gemcitabine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a phase 3 randomised, double-blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 43.1 of the RMP has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Pralsetinib - GAVRETO (CAP) - EMEA/H/C/005413/II/0012

Applicant: Roche Registration GmbH
PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.2, 4.4 and 4.5 of the SmPC in order to amend posology recommendations, warnings and drug-drug interaction (DDI) information regarding the co-administration with CYP3A4 inhibitors, P-gp inhibitors and CYP3A4 inducers based on final results from the DDI study GP43162, listed as a category 3 study in the RMP, as well as results from the physiologically based pharmacokinetic (PBPK) analyses summarised in the PBPK Report 1120689. Study GP43162 is a phase 1, open-label, fixed-sequence study to evaluate the effect of a single dose of cyclosporine on the single dose pharmacokinetics of pralsetinib in healthy subjects. The RMP version 1.6 has also been submitted.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Saxagliptin - ONGLYZA (CAP) - EMEA/H/C/001039/II/0057

Applicant: AstraZeneca AB
PRAC Rapporteur: Menno van der Elst

Scope: Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information in paediatric patients with Type 2 diabetes mellitus (T2DM) aged 10 to <18 years of age based on interim results from study D1680C00019 (T2NOW). This is a 26-week, multicentre, randomised, placebo-controlled, double-blind, parallel group, Phase III trial with a 26-week safety extension period evaluating the safety and efficacy of dapagliflozin (5 and 10 mg), and, separately, saxagliptin (2.5 and 5 mg) in paediatric patients with T2DM who were between 10 and below 18 years of age. The package leaflet is updated accordingly. The RMP version 17.1 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template and to introduce editorial changes.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.27. **Selexipag - UPTRAVI (CAP) - EMEA/H/C/003774/X/0038**

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Nathalie Gault

Scope: Extension application to add a new strength of 100 µg film-coated tablets in HDPE bottle. The RMP (version 10.1) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. **Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0021**

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET) fusion-positive thyroid cancer in the first-line setting for RETSEVMO based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an open-label, multicentre, global phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumors. LIBRETTO-121 is a phase 1/2 study of selpercatinib in paediatric patients with advanced RET-altered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. **Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0022**

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include the treatment of adults with advanced or metastatic rearranged during transfection (RET) fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. **Sotorasib - LUMYKRAS (CAP) - EMEA/H/C/005522/II/0007**

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations for patients with moderate to severe hepatic impairment following final results from study
20200362 listed as a category 3 PASS study in the EU RMP; this is a Phase I clinical study to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in subjects with moderate or severe hepatic impairment compared with subjects who have normal hepatic function. The EU RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.31. Spesolimab - SPEVIGO (CAP) - EMEA/H/C/005874/X/0006/G

**Applicant:** Boehringer Ingelheim International GmbH

**PRAC Rapporteur:** Nathalie Gault

**Scope:** Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (150 mg) and new route of administration (subcutaneous use), for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. This line extension is grouped with a type II variation (C.I.6.a) to extend indication for Spevigo 450 mg concentrate for solution for infusion to include treatment of generalised pustular psoriasis (GPP) flares in adolescents (from 12 years of age), based on final results from study 1368-0027 (Effisayil 2) and extrapolation; this is a multi-centre, randomised, parallel group, double blind, placebo controlled, phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (spesolimab) compared to placebo in preventing GPP flares in patients with history of GPP. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Annex II and package leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce editorial changes to the product information and update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.32. Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/004090/II/0075, Orphan

**Applicant:** Novartis Europharm Limited, ATMP7

**PRAC Rapporteur:** Gabriele Maurer

**Scope:** Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTL019C2201 PAES in the Annex II (ANX008); this is a Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The RMP version 6 has also been submitted. In addition, the MAH took the opportunity to update Annex II.D of the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

---

7 Advanced therapy medicinal product
5.3.33. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0188/G

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Grouped application comprising two type II variations as follows:
C.I.4 – 1) Update of section 4.8 of the SmPC in order to update the safety information based on interim (6MPD3 in 12-15yo) and final results from study C4591001, listed as a category 3 study in the RMP. This is a phase 1/2/3, placebo-controlled, randomised, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. An updated RMP version 10.1 has also been submitted.
C.I.11.b – 2) Submission of an updated RMP version 10.1 in order to revise RMP milestones of final study reports of other on-going procedures, including other administrative and editorial changes

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Avacopan - TAVNEOS (CAP) - PSUSA/00010967/202303

Applicant: Vifor Fresenius Medical Care Renal Pharma France
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.2. Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202303

Applicant: Merck Europe B.V.
PRAC Rapporteur: Karin Erneholm
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.3. Betaine anhydrous8 - CYSTADANE (CAP) - PSUSA/00000390/202302

Applicant: Recordati Rare Diseases
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure

---

8 Centrally authorised product(s) only
**Action:** For adoption of recommendation to CHMP

### 6.1.4. Bupivacaine, meloxicam - ZYNRELEF<sup>9</sup> - PSUSA/00010880/202303

- **Applicant:** Heron Therapeutics, B.V.
- **PRAC Rapporteur:** Liana Gross-Martirosyan
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For discussion

### 6.1.5. Cabotegravir - VOCABRIA (CAP) - PSUSA/00010900/202303

- **Applicant:** ViiV Healthcare B.V.
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.6. Cenobamate - ONTOZRY (CAP) - PSUSA/00010921/202303

- **Applicant:** Angelini S.p.A.
- **PRAC Rapporteur:** Jo Robays
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.7. Certolizumab - CIMZIA (CAP) - PSUSA/00000624/202303

- **Applicant:** UCB Pharma S.A.
- **PRAC Rapporteur:** Mari Thorn
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.8. Ciclosporin<sup>10</sup> - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202303

- **Applicant:** Santen Oy
- **PRAC Rapporteur:** Jan Neuhauser
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

---

<sup>9</sup> European Commission (EC) decision on the marketing authorisation (MA) withdrawal of Zynrelef dated 05 October 2023

<sup>10</sup> For topical use only
6.1.9. **Dabigatran - PRADAXA (CAP) - PSUSA/00000918/202303**

Applicant: Boehringer Ingelheim International GmbH
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.10. **Dimethyl fumarate\(^{11}\) - SKILARENCE (CAP) - PSUSA/00010647/202303**

Applicant: Almirall S.A
PRAC Rapporteur: Mari Thorn
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.11. **Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202303**

Applicant: Sanofi Winthrop Industrie
PRAC Rapporteur: Kimmo Jaakkola
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.12. **Duvelisib - COPIKTRA (CAP) - PSUSA/00010939/202303**

Applicant: Secura Bio Limited
PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.13. **Eftrenonacog alfa - ALPROLIX (CAP) - PSUSA/00010499/202303**

Applicant: Swedish Orphan Biovitrum AB (publ)
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.14. **Filgotinib - JYSELECA (CAP) - PSUSA/00010879/202303**

Applicant: Galapagos N.V.
PRAC Rapporteur: Nikica Mirošević Skvrce

\(^{11}\) Psoriasis
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.15. Fingolimod - GILENYA (CAP) - PSUSA/00001393/202302

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.16. Gozetotide - LOCAMETZ (CAP) - PSUSA/00011030/202303

Applicant: Novartis Europharm Limited

PRAC Rapporteur: John Joseph Borg

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.17. Ibritumomab tiuxetan - ZEVALIN (CAP) - PSUSA/00001704/202302

Applicant: Ceft Biopharma s.r.o.

PRAC Rapporteur: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.18. Idecabtagene vicleucel - ABECMA (CAP) - PSUSA/00010954/202303

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP\(^{12}\)

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CAT and CHMP

### 6.1.19. Lasmiditan - RAYVOW (CAP) - PSUSA/00011011/202304

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Anna Mareková

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

\(^{12}\) Advanced therapy medicinal product
6.1.20. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202303

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.21. Lutetium (177LU) vipivotide tetraxetan - PLUVICTO (CAP) - PSUSA/00011031/202303

Applicant: Novartis Europharm Limited
PRAC Rapporteur: John Joseph Borg
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.22. Maralixibat - LIVMARLI (CAP) - PSUSA/00011032/202303

Applicant: Mirum Pharmaceuticals International B.V.
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.23. Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202303

Applicant: GlaxoSmithKline Trading Services Limited
PRAC Rapporteur: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.24. Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202303

Applicant: Kyowa Kirin Holdings B.V.
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.25. Niraparib - ZEJULA (CAP) - PSUSA/00010655/202303

Applicant: GlaxoSmithKline (Ireland) Limited
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP


- **Applicant:** Bristol-Myers Squibb Pharma EEIG
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.27. Ofatumumab - KESIMPTA (CAP) - PSUSA/00010927/202303

- **Applicant:** Novartis Ireland Limited
- **PRAC Rapporteur:** Amelia Cupelli
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.28. Olipudase alfa - XENPOZYME (CAP) - PSUSA/00011003/202303

- **Applicant:** Sanofi B.V.
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.29. Oritavancin - TENKASI (CAP) - PSUSA/00010368/202303

- **Applicant:** Menarini International Operations Luxembourg S.A.
- **PRAC Rapporteur:** Adam Przybylkowski
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.30. Ponesimod - PONVORY (CAP) - PSUSA/00010940/202303

- **Applicant:** Janssen-Cilag International N.V.
- **PRAC Rapporteur:** Karin Erneholm
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CHMP

### 6.1.31. Rilpivirine\(^\text{13}\) - REKAMBYS (CAP) - PSUSA/00010901/202303

- **Applicant:** Janssen-Cilag International N.V.

\(^\text{13}\) For intramuscular use only
6.1.32. **Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202303**

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.33. **Selinexor - NEXPOVIO (CAP) - PSUSA/00010926/202303**

Applicant: Stemline Therapeutics B.V.
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.34. **Selumetinib - KOSELUGO (CAP) - PSUSA/00010936/202304**

Applicant: AstraZeneca AB
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.35. **Siponimod - MAYZENT (CAP) - PSUSA/00010818/202303**

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.36. **Solriamfetol - SUNOSI (CAP) - PSUSA/00010831/202303**

Applicant: Atnahs Pharma Netherlands B.V.
PRAC Rapporteur: Julia Pallos
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP
6.1.37. Tebentafusp - KIMMTRAK (CAP) - PSUSA/00010991/202303

Applicant: Immunocore Ireland Limited
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.38. Tepotinib - TEPMETKO (CAP) - PSUSA/00010979/202303

Applicant: Merck Europe B.V.
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.39. Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202303

Applicant: Almirall S.A
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.40. Trifluridine, tipiracil - LONSURF (CAP) - PSUSA/00010517/202303

Applicant: Les Laboratoires Servier
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.41. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202303

Applicant: Chiesi Farmaceutici S.p.A.
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP
6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

6.2.1. **Pramipexole - MIRAPEXIN (CAP); SIFROL (CAP); NAP - PSUSA/00002491/202304**

Applicant: Boehringer Ingelheim International GmbH (Mirapexin, Sifrol), various
PRAC Rapporteur: Karin Erneholm
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.2.2. **Timolol, travoprost - DUOTRAV (CAP); NAP - PSUSA/00002962/202302**

Applicant: Novartis Europharm Limited (DuoTrav), various
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. **BCG (bacillus calmette-guérin) for Immunotherapy (NAP) - PSUSA/00000303/202303**

Applicant(s): various
PRAC Lead: Gabriele Maurer
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.2. **BCG vaccine (freeze-dried) (NAP) - PSUSA/00000304/202303**

Applicant(s): various
PRAC Lead: Roxana Dondera
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.3. **Bicalutamide (NAP) - PSUSA/00000407/202302**

Applicant(s): various
PRAC Lead: Karin Erneholm
Scope: Evaluation of a PSUSA procedure
### 6.3.4. Dienogest, ethinylestradiol (NAP) - PSUSA/00001057/202303

- **Applicant(s):** various
- **PRAC Lead:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.5. Ethosuximide (NAP) - PSUSA/00001316/202303

- **Applicant(s):** various
- **PRAC Lead:** Karin Erneholm
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.6. Fluconazole (NAP) - PSUSA/00001404/202303

- **Applicant(s):** various
- **PRAC Lead:** Marie Louise Schougaard Christiansen
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.7. Furosemide, spironolactone (NAP) - PSUSA/00001493/202303

- **Applicant(s):** various
- **PRAC Lead:** Karin Erneholm
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.8. Human plasma\(^\text{14}\) (NAP) - PSUSA/00001635/202302

- **Applicant(s):** various
- **PRAC Lead:** Gabriele Maurer
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

### 6.3.9. Oxycodone (NAP) - PSUSA/00002254/202304

- **Applicant(s):** various

---
\(^{14}\) Pooled and treated for virus inactivation
PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.4. Follow-up to PSUR/PSUSA procedures

#### 6.4.1. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/LEG 017.2

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Eva Jirsová

Scope: From II-0031: Commitment to provide targeted tumour lysis syndrome (TLS) assessment reports on a biannual basis (submitted annually within the PSUR, and 6 months after the PSUR submission in a separate report) through 2023, and annually thereafter, as per the RMP v8.0. These biannual assessment reports ensure close monitoring of the important identified risk of TLS, and the evaluation of the impact of newly implemented risk minimisation measures for TLS, on adherence to both already existing and updated recommendation added to the SmPC, the impact of the DHPC distributed to haematologists, and the patient card

**Action:** For adoption of advice to CHMP

### 6.5. Variation procedure(s) resulting from PSUSA evaluation

#### 6.5.1. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0243

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Mari Thorn

Scope: To update section 4.8 of the SmPC to add weight increased to the list of adverse drug reactions (ADRs) with frequency uncommon following PRAC PSUR assessment report (EMA/PRAC/158162/2023-Corr.1) based on the cumulative literature review. The package leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce minor editorial changes

**Action:** For adoption of PRAC Assessment Report

#### 6.5.2. Laronidase - ALDURAZYME (CAP) - EMEA/H/C/000477/II/0085

Applicant: Sanofi B.V.

PRAC Rapporteur: Nathalie Gault

Scope: To update section 4.2 of the SmPC in order to modify the administration instructions following the periodic safety update single assessment (PSUSA) procedure (PSUSA/00001830/202104) adopted in December 202115 based on literature review. The package leaflet is updated accordingly. The RMP version 1.0 has also been submitted

---

15 Held 29 November – 02 December 2021
**Action:** For adoption of PRAC Assessment Report

### 6.6. Expedited summary safety reviews

None

### 7. Post-authorisation safety studies (PASS)

#### 7.1. Protocols of PASS imposed in the marketing authorisation(s)

**7.1.1. Alemtuzumab - Lemtrada (CAP) - EMEA/H/C/PSA/S/0107**

- **Applicant:** Blueprint Medicines (Netherlands) B.V.
- **PRAC Rapporteur:** Karin Erneholm
- **Scope:** Substantial amendment to the protocol of a non-interventional PASS to investigate drug utilisation and safety monitoring patterns for Lemtrada (alemtuzumab)
- **Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

**7.1.2. Valproate (NAP) - EMEA/H/N/PSP/J/0075.13**

- **Applicant:** Sanofi-Aventis Recherche & Développement (on behalf of a consortium)
- **PRAC Rapporteur:** Liana Gross-Martirosyan
- **Scope:** Responses to the 2nd RSI of the 4th interim report and statistical analysis plan for drug utilisation study (DUS) extension (DUS ext.) to assess the effectiveness of the new risk minimisation measures and to further characterise the prescribing patterns for valproate and related substances [MAH's response to PSP/J/0075.12]
- **Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

#### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)

**7.2.1. Avatrombopag - DOPTELET (CAP) - EMEA/H/C/004722/MEA 003.4**

- **Applicant:** Swedish Orphan Biovitrum AB (publ)
- **PRAC Rapporteur:** Monica Martinez Redondo
- **Scope:** MAH's response to MEA 003.3 and revised protocol for a study to further characterise the long-term safety profile of avatrombopag in patients with primary chronic

---

16 Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

17 In accordance with Article 107n of Directive 2001/83/EC

18 Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

19 In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
immune thrombocytopenia in European patient registers and electronic healthcare databases as requested in the conclusions of variation II/0004/G finalised in December 2020 as per the request for supplementary information (RSI) adopted June 2023.

**Action:** For adoption of advice to CHMP

### 7.2.2. Cannabidiol - EPIDYOLEX (CAP) - EMEA/H/C/004675/MEA 007.3

**Applicant:** Jazz Pharmaceuticals Ireland Limited

**PRAC Rapporteur:** Ana Sofia Diniz Martins

**Scope:** MAH’s response to MEA 007.2 [protocol amendment for study GWEP19022 (listed as a category 3 study in the RMP): a prospective, observational cohort long-term safety study to assess the potential for chronic liver injury in patients treated with Epidyolex (cannabidiol oral solution) when used under conditions of routine clinical care] as per the request for supplementary information (RSI) adopted in July 2021.

**Action:** For adoption of advice to CHMP

### 7.2.3. Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - EMEA/H/C/006058/MEA 008

**Applicant:** Hipra Human Health S.L.

**PRAC Rapporteur:** Zane Neikena

**Scope:** Protocol submission for the non-imposed, non-interventional, category 3 post authorisation observational study to assess the safety of Bimervax using electronic health record (HER) databases in Europe (PASS VAC4EU).

**Action:** For adoption of advice to CHMP

### 7.2.4. Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - EMEA/H/C/006058/MEA 009

**Applicant:** Hipra Human Health S.L.

**PRAC Rapporteur:** Zane Neikena

**Scope:** Protocol submission for the non-imposed, non-interventional, category 3 PASS of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) to assess the occurrence of obstetric, neonatal, and infant outcomes among women administered with Bimervax during pregnancy.

**Action:** For adoption of advice to CHMP

### 7.2.5. Ivosidenib - TIBSOVO (CAP) - EMEA/H/C/005936/MEA 003

**Applicant:** Les Laboratoires Servier

**PRAC Rapporteur:** Marie Louise Schougaard Christiansen

**Scope:** Protocol submission for a non-imposed/non-interventional, category 3 study in the RMP to evaluate the effectiveness of the Ivosidenib Patient Alert Card included in the
additional risk minimisation measures, for awareness of differentiation syndrome in acute
myeloid leukaemia (AML) patients, using process indicators for awareness, receipt of the
material, utility and knowledge

**Action:** For adoption of advice to CHMP

### 7.2.6. Linaclotide - CONSTELLA (CAP) - EMEA/H/C/002490/MEA 009.7

**Applicant:** AbbVie Deutschland GmbH & Co. KG

**PRAC Rapporteur:** Martin Huber

**Scope:** Amendment to a protocol previously agreed for PASS EVM-18888: linaclotide safety study assessing the complications of diarrhoea and associated risk factors in selected European populations with irritable bowel syndrome with constipation (IBS-C) for Constella (linaclotide) 290μg capsule (protocol version 13)

**Action:** For adoption of advice to CHMP

### 7.2.7. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 001

**Applicant:** Bristol-Myers Squibb Pharma EEIG

**PRAC Rapporteur:** Kimmo Jaakkola

**Scope:** Submission of protocol for a non-imposed, non-interventional post-authorisation long-term observational study in Europe (MAVEL-HCM) in a real-world setting in patients with obstructive hypertrophic cardiomyopathy (oHCM) to characterise the following safety concerns: ‘heart failure due to systolic dysfunction’, ‘patients with Class IV NYHA’, ‘patients being treated with disopyramide’, ‘patients being treated with a combination of β-blockers and non-dihydropyridine calcium-channel blockers (verapamil/diltiazem)’, and ‘long-term safety, including detrimental CV effects’

**Action:** For adoption of advice to CHMP

### 7.2.8. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 002

**Applicant:** Bristol-Myers Squibb Pharma EEIG

**PRAC Rapporteur:** Kimmo Jaakkola

**Scope:** Submission of a protocol for a non-imposed, non-interventional (CV027-1148) meta-analysis of phase 3, placebo-controlled, double-blind, randomised studies of mavacamten in patients with symptomatic hypertrophic cardiomyopathy (HCM), to evaluate the cardiovascular safety profile based on a composite endpoint of time to first occurrence of major cardiovascular event (MACE) meta-analysis event, including three clinical trials in symptomatic obstructive hypertrophic cardiomyopathy (HCM) population (EXPLORER-HCM, VALOR-HCM, China oHCM Phase 3 trial) and one clinical trial in symptomatic non-obstructive HCM population (ODYSSEY-HCM)

**Action:** For adoption of advice to CHMP
7.2.9. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.7

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: MAH's response to MEA 001.6 [protocol amendment for study OP0005: a European non-interventional PASS to study the adherence to the risk minimisation measures (RMMs) in the product information by estimating the compliance with contraindications and target indication(s) amongst incident romosozumab users, and analysing the utilisation pattern using the EU-adverse drug reactions (EU-ADR) Alliance] as per the request for supplementary information adopted in July 2023
Action: For adoption of advice to CHMP

7.2.10. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.7

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: MAH's response to MEA 002.6 [protocol amendment for study OP0004: European non-interventional PASS to evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance] as per the request for supplementary information adopted in July 2023
Action: For adoption of advice to CHMP

7.2.11. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.5

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: MAH's response to MEA 003.4 [protocol amendment for study OP0006: evaluate potential differences in terms of serious infection between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance] as per the request for supplementary information adopted in July 2023
Action: For adoption of advice to CHMP

7.2.12. Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 002.1

Applicant: Eli Lilly Nederland B.V.
PRAC Rapporteur: Menno van der Elst
Scope: MAH's response to MEA 002 [protocol for study I8F-MC-B011: Tirzepatide Pancreatic Malignancy Study to evaluate the incidence of pancreatic malignancy among patients with type 2 diabetes mellitus (T2DM) treated with tirzepatide and to compare the incidence of pancreatic malignancy among patients treated with tirzepatide to patients treated with alternative treatments for clinical indications approved for GLP-1 Ras in Europe] as per the request for supplementary information adopted in April 2023
**Action:** For adoption of advice to CHMP

### 7.2.13. Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 005.1

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Menno van der Elst

**Scope:** MAH's response to MEA 005 [protocol for study I8F-MC-B013: a database linkage study to evaluate the important potential risk of medullary thyroid cancer] as per the request for supplementary information adopted in April 2023

**Action:** For adoption of advice to CHMP

### 7.2.14. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 037.5

**Applicant:** BioNTech Manufacturing GmbH

**PRAC Rapporteur:** Menno van der Elst

**Scope:** MAH's response to MEA 037.4 [A non-interventional PASS in US to assess the occurrence of safety events of interest, including myocarditis and pericarditis, among individuals in the general US population and in subcohorts of interest within selected data sources participating in the US Sentinel System] as per request for supplementary information (RSI) adopted in February 2023

**Action:** For adoption of advice to CHMP

### 7.2.15. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 017.1

**Applicant:** AbbVie Deutschland GmbH & Co. KG

**PRAC Rapporteur:** Nikica Mirošević Skvrce

**Scope:** Revised protocol for study P23-480: a comparative cohort study of long-term safety of upadacitinib for the treatment of ulcerative colitis and Chron's disease in a real-world setting in Europe

**Action:** For adoption of advice to CHMP

### 7.2.16. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 044.17

**Applicant:** Janssen-Cilag International N.V.

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** MAH's response to MEA 044.16 [PASS CNTO1275PSO4056] as per request for supplementary information (RSI) adopted in June 2023:

- Progress report / Request for supplementary information required by 7 August 2023:
  - The MAH is asked to provide further information on the following events, considered by the investigator related to ustekinumab: Tinea versicolor, Balanitis candida

**Action:** For adoption of advice to CHMP
7.2.17. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - EMEA/H/C/005830/MEA 005.1

Applicant: BioMarin International Limited, ATMP20
PRAC Rapporteur: Menno van der Elst
Scope: MAH’s response to MEA 005 [Protocol of a survey of Haematologists to Assess the Effectiveness of the Additional Risk Minimisation Measures for ROCTAVIAN addressing the outstanding points in the MEA005 assessment report] as per request for supplementary information (RSI) adopted in June 2023

Action: For adoption of advice to CAT and CHMP

7.2.18. Voclosporin - LUPKYNIS (CAP) - EMEA/H/C/005256/MEA 002.1

Applicant: Otsuka Pharmaceutical Netherlands B.V.
PRAC Rapporteur: Adam Przybylkowski
Scope: MAH's response to MEA 002 [protocol No 348-201-00021: non-imposed/non-interventional, listed as category 3 study in the RMP, observational PASS in Europe to further characterise and quantify long-term safety profile with respect to neurotoxicity, chronic nephrotoxicity, and malignancy with use of voclosporin] as per the request for supplementary information (RSI) adopted in June 2023

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)21

7.3.1. Valproate22 (NAP) - EMEA/H/N/PSR/J/0043

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Final study report for a retrospective observational study to investigate the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring

Action: List of experts and list of questions (LoQ) for stakeholder’s meeting/SAG

7.3.2. Valproate23 (NAP) - EMEA/H/N/PSR/J/0045

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)
PRAC Rapporteur: Jean-Michel Dogné
Scope: Final study report for a non-interventional retrospective longitudinal study in the United Kingdom and France to investigate the therapeutic strategies after discontinuation of valproate and related substances in clinical practice

---

20 Advanced therapy medicinal product
21 In accordance with Article 107p-q of Directive 2001/83/EC
22 Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valprimide, valproate bismuth, calcium valproate, valproate magnesium
23 Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valprimide, valproate bismuth, calcium valproate, valproate magnesium
**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

### 7.4. Results of PASS non-imposed in the marketing authorisation(s)\(^ {24} \)

#### 7.4.1. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0093

Applicant: Sanofi B.V.

PRAC Rapporteur: Nathalie Gault

Scope: Submission of the final non-interventional Pompe Registry Report 2022 (MEA024 and MEA025)

**Action:** For adoption of PRAC Assessment Report

#### 7.4.2. Belimumab - BENLYSTA (CAP) - EMEA/H/C/002015/II/0116

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report for the belimumab pregnancy registry (BPR) (BEL114256) listed as a category 3 study in the RMP. This is a non-interventional study to evaluate pregnancy and infant outcomes for pregnancies in women with systemic lupus erythematosus (SLE) exposed to commercially supplied belimumab within the 4 months preconception and/or during pregnancy. In addition, the BPR protocol planned to collect pregnancy and infant outcomes for pregnancies in women with SLE and Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus (SABLE) protocol who were not exposed to belimumab and enrolled in BPR. The RMP version 45.0 has also been submitted

**Action:** For adoption of PRAC Assessment Report

#### 7.4.3. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0082

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy based on results from study 109MS402 - Tecfidera (dimethyl fumarate) Pregnancy Exposure Registry, listed as a category 3 study in the RMP; this is an observational study and aims to address the safety concern of effects on pregnancy outcome and prospectively evaluates pregnancy outcomes in women with multiple sclerosis (MS) who were exposed to a Registry-specified Biogen MS product during the eligibility window for that product. The package leaflet is updated accordingly. The RMP version 15.1 has also been submitted. In addition, the MAH has taken the opportunity to introduce editorial changes to the product information

**Action:** For adoption of PRAC Assessment Report

---

\(^ {24} \) In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
7.4.4. Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0110

Applicant: Moderna Biotech Spain, S.L.
PRAC Rapporteur: Marie Louise Schougaard Christiansen
Scope: Submission of the final report from study P903 - US PASS (NCT04958954), listed as a category 3 study in the RMP: post-marketing safety of SARS-CoV-2 Spikevax vaccine in the US for the active surveillance, signal refinement and self-controlled risk interval (SCRI) signal evaluation in HealthVerity. This submission addresses the post-authorisation measure MEA/003
Action: For adoption of PRAC Assessment Report

7.4.5. Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/WS2519/0071/G; MODIGRAF (CAP) - EMEA/H/C/000954/WS2519/0046/G

Applicant: Astellas Pharma Europe B.V.
PRAC Rapporteur: Eamon O Murchu
Scope: A grouped application consisting of: 1) submission of the final report from study F506-PV-0001 listed as a category 3 study in the RMP for Advagraf and Modigraf: NI-PASS of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from Transplant Pregnancy Registry International (TPRI). The RMP version 5.0 has also been submitted; and 2) to include the feasibility assessment of using alternative secondary-use data sources to replicate the TPRI study as a category 3 additional pharmacovigilance activity in the RMP, including the milestones for the progress report and the final report of the feasibility assessment, related to EMEA/H/C/000712/MEA/032 and EMEA/H/C/000954/MEA/024
Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/SOB 009.1

Applicant: Blueprint Medicines (Netherlands) B.V.
PRAC Rapporteur: Menno van der Elst
Scope: Study BLU-285-1406 is an imposed non-interventional PASS aiming to confirm the safety and efficacy of avapritinib in the treatment of adult patients with unresectable or metastatic GIST harbouring the PDGFRA D842V mutation, given as Specific Obligation 3 (SOB3) of the Conditional Marketing Authorisation for AYVAKYT. The submission of the first progress report is in line with agreed milestones in the Final PASS Protocol Assessment Report from the Pharmacovigilance Risk Assessment Committee (procedure number EMEA/H/C/PSP/S/0089.1 issued on 10 June 2021)
Action: For adoption of advice to CHMP
7.5.2. **Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/004480/ANX 002.6**

Applicant: Kite Pharma EU B.V., ATMP

PRAC Rapporteur: Karin Erneholm

Scope: Title: Long-term, non-interventional study of recipients of Yescarta for treatment of relapsed or refractory Diffuse Large B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma

**Action:** For adoption of advice to CAT and CHMP

7.5.3. **Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 005**

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: From Initial MAA: Study PS0014: A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate-to-severe chronic plaque PSO. Assess the safety and efficacy of long-term use of bimekizumab

**Action:** For adoption of advice to CHMP

7.5.4. **Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.9**

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: From Initial MAA: C-VIPER Study (D8110C00003); COVID-19 Vaccines International Pregnancy Registry of Women Exposed to AZD1222 Immediately Before or During Pregnancy

**Action:** For adoption of advice to CHMP

7.5.5. **Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 002**

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Mari Thorn

Scope: A Multicenter, Randomised, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus and Not on Dialysis With an up to 52-Week Long-term Extension

**Action:** For adoption of advice to CHMP

7.5.6. **Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 003**

Applicant: Vifor Fresenius Medical Care Renal Pharma France

---

25 Advanced therapy medicinal product
PRAC Rapporteur: Mari Thorn
Scope: A Multicenter, Randomised, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus and Not on Dialysis With an up to 52-Week Long-term Extension
Action: For adoption of advice to CHMP

7.5.7. Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 004
Applicant: Vifor Fresenius Medical Care Renal Pharma France
PRAC Rapporteur: Mari Thorn
Scope: A Two-part, Multicenter, Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis
Action: For adoption of advice to CHMP

7.5.8. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/MEA 006.6
Applicant: Alnylam Netherlands B.V.
PRAC Rapporteur: Martin Huber
Scope: From Initial MAA: Company Sponsored AHP Registry; A global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP)
Action: For adoption of advice to CHMP

7.5.9. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/MEA 003.15
Applicant: Orexigen Therapeutics Ireland Limited
PRAC Rapporteur: Martin Huber
Scope: PASS Study NB-451: An observational retrospective drug utilisation study (DUS) of Mysimba (naltrexone hydrochloride/bupropion hydrochloride) in Europe and the United States to describe the demographic and baseline characteristics of users of Mysimba, evaluate patterns of Mysimba initiation and use
Action: For adoption of advice to CHMP

7.6. Others
None

7.7. New Scientific Advice
None
7.8. **Ongoing Scientific Advice**

None

7.9. **Final Scientific Advice (Reports and Scientific Advice letters)**

None

8. **Renewals of the marketing authorisation, conditional renewal and annual reassessments**

8.1. **Annual reassessments of the marketing authorisation**

8.1.1. **Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0062 (without RMP)**

Applicant: Sandoz Pharmaceuticals d.d.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

8.1.2. **Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0036 (without RMP)**

Applicant: Ultragenyx Germany GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

8.2. **Conditional renewals of the marketing authorisation**

None

8.3. **Renewals of the marketing authorisation**

8.3.1. **Lusutrombopag - MULPLEO (CAP) - EMEA/H/C/004720/R/0018 (without RMP)**

Applicant: Shionogi B.V.

PRAC Rapporteur: Mari Thorn

Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP
8.3.2. Paclitaxel - PAZENIR (CAP) - EMEA/H/C/004441/R/0015 (with RMP)

Applicant: ratiopharm GmbH
PRAC Rapporteur: Menno van der Elst
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.3. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/R/0038 (without RMP)

Applicant: BioMarin International Limited
PRAC Rapporteur: Rhea Fitzgerald
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.4. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/R/0039 (without RMP)

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.5. Treosulfan - TRECONDI (CAP) - EMEA/H/C/004751/R/0019 (without RMP)

Applicant: medac Gesellschaft fur klinische Spezialpraparate mbH
PRAC Rapporteur: Julia Pallos
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.6. Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/R/0017 (without RMP)

Applicant: GlaxoSmithKline Trading Services Limited
PRAC Rapporteur: Ulla Wändel Liminga
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None
9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States’ safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

None

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

11.1.1. Hydroxyethyl starch (NAP) - DE/H/xxxx/WS/1360, DE/H/xxxx/WS/1452

Applicant(s): Fresenius Kabi Deutschland GmbH, Fresenius Kabi Polska Sp. Z O.O.
PRAC Lead: Martin Huber
Scope: PRAC consultation on two worksharing variation (WS) procedures (DE/H/xxxx/WS/1360 and DE/H/xxxx/WS/1452) related to the assessment of the final results from two imposed clinical trials (PHOENICS and TETHYS), to the update of the risk management plan (RMP) and product information, as well as to the dissemination of a proposed direct healthcare professional communication (DHPC) in order to fulfil the
conditions for lifting the suspension of marketing authorisations adopted by the Commission on 24 May 2022, on request of Germany

**Action:** For adoption of advice to Member States

### 11.2. Other requests

None

### 12. Organisational, regulatory and methodological matters

#### 12.1. Mandate and organisation of the PRAC

**12.1.1. PRAC membership**

**Action:** For information

**12.1.2. Vote by proxy**

None

#### 12.2. Coordination with EMA Scientific Committees or CMDh-v

None

#### 12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

#### 12.4. Cooperation within the EU regulatory network

**12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update**

**Action:** For discussion

**12.4.2. PRAC strategic review and learning meeting (SRLM) under the Spanish presidency of the European Union (EU) Council – Madrid, Spain, 14 - 15 November 2023 - agenda**

PRAC lead: Maria del Pilar Rayon, Monica Martinez Redondo

**Action:** For discussion
12.5. **Cooperation with International Regulators**
None

12.6. **Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee**
None

12.7. **PRAC work plan**
None

12.8. **Planning and reporting**

12.8.1. **EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q3 2023 and predictions**

**Action**: For discussion

12.8.2. **PRAC workload statistics – Q3 2023**

**Action**: For discussion

12.9. **Pharmacovigilance audits and inspections**

12.9.1. **Pharmacovigilance systems and their quality systems**
None

12.9.2. **Pharmacovigilance inspections**
None

12.9.3. **Pharmacovigilance audits**
None

12.10. **Periodic safety update reports (PSURs) & Union reference date (EURD) list**

12.10.1. **Periodic safety update reports**
None
12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla

**Action:** For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

**Action:** For adoption

12.10.5. Periodic safety update reports single assessment (PSUSA) – review of ‘other considerations’ section in the assessment report – update and proposed way forward

PRAC lead(s): Sabine Straus, Martin Huber

**Action:** For discussion

12.11. Signal management


None

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

**Action:** For adoption
12.13. **EudraVigilance database**

12.13.1. **Activities related to the confirmation of full functionality**

None


12.14.1. **Risk management systems**

None

12.14.2. **Tools, educational materials and effectiveness measurement of risk minimisations**

None

12.15. **Post-authorisation safety studies (PASS)**

12.15.1. **Post-authorisation Safety Studies – imposed PASS**

None

12.15.2. **Post-authorisation Safety Studies – non-imposed PASS**

None

12.16. **Community procedures**

12.16.1. **Referral procedures for safety reasons**

None

12.17. **Renewals, conditional renewals, annual reassessments**

None

12.18. **Risk communication and transparency**

12.18.1. **Public participation in pharmacovigilance**

None
12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. Good Pharmacovigilance Practice (GVP) – end-of-year update for 2023 and planning for 2024

PRAC lead: Sabine Straus

Action: For discussion

12.21.2. Presentation of draft reflection paper on ‘Use of real-world data to generate real-world evidence in non-interventional studies’

Action: For discussion

13. Any other business

Next meeting on: 27-30 November 2023
14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks. The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event. The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

For a list of acronyms and abbreviations, see: List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in
Pharmacovigilance Risk Assessment Committee (PRAC)

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)